tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Changmao Biochemical Reports Increased Losses and Revenue Decline for H1 2025

Story Highlights
Changmao Biochemical Reports Increased Losses and Revenue Decline for H1 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Changmao Biochemical Engineering Co. Ltd. Class H ( (HK:0954) ) is now available.

Changmao Biochemical Engineering Co. Ltd. reported its interim results for the six months ended June 30, 2025, showing a decrease in revenue to RMB 272,278,000 from RMB 313,802,000 in the same period in 2024. The company also reported a loss attributable to shareholders of RMB 25,790,000, compared to a loss of RMB 18,786,000 in the previous year, and the directors do not recommend an interim dividend for this period.

More about Changmao Biochemical Engineering Co. Ltd. Class H

Changmao Biochemical Engineering Co. Ltd. is a joint stock limited company incorporated in the People’s Republic of China, operating in the biochemical engineering industry. The company is listed on the Hong Kong Stock Exchange under the stock code 954.

YTD Price Performance: -20.0%

Average Trading Volume: 190,846

Technical Sentiment Signal: Sell

Current Market Cap: HK$169.5M

Find detailed analytics on 0954 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1